http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Andrea Luk (검색결과 3 건)
- 무료
- 기관 내 무료
- 유료
-
Gani, Linsey,Lau, Eric,Luk, Andrea,Sobrepena, Leorino,Tran, Quang Khanh,Kesavadev, Jothydev,Jia, Weiping,Yu, Weinan,Tsang, Chiu Chi,Mukhopadhyay, Monojitketan,Jha, Sujeet,Sheu, Wayne,Ho, Yoon Kun,Nguy John Wiley and Sons Inc. 2018 Journal of diabetes investigation Vol.9 No.6
<P><B>Abstract</B></P><P><B>Aims/Introduction</B></P><P>Biosimilar insulin can reduce treatment costs, although the extent of its use is largely unknown. We examined biosimilar insulin use and its associations with the quality of glycemic control using the Joint Asia Diabetes Evaluation register.</P><P><B>Materials and Methods</B></P><P>We carried out a cross‐sectional analysis in 81,531 patients with type 1 and type 2 diabetes enrolled into the Joint Asia Diabetes Evaluation Program from 2007 to 2014. All insulin related terms are extracted from the Joint Asia Diabetes Evaluation portal, and compared clinical profiles between biosimilar and originator insulin users. Multivariate analysis was performed to assess the association of biosimilar insulin compared with originator insulin with dosage, glycated hemoglobin and hypoglycemia events.</P><P><B>Results</B></P><P>Amongst 81,531 patients, 20.5% (<I>n</I> = 16,738) were insulin‐treated. In four countries with high use of biosimilar insulin, 4.7% (<I>n</I> = 719) of insulin users (<I>n</I> = 10,197) were treated with biosimilar insulin (India <I>n</I> = 507, 70.3%; the Philippines <I>n</I> = 90, 12.5%; China <I>n</I> = 62, 8.6%; Vietnam <I>n</I> = 60, 8.3%). Biosimilar insulin users were younger and had higher body mass index, glycated hemoglobin, insulin dosage and more frequent hypoglycemia than originator insulin users. These associations were non‐significant after adjustment for confounders. Only age, college education, diabetes education, lipid control, physical activity and history of cardiovascular complications were independently associated with these quality measures.</P><P><B>Conclusions</B></P><P>Biosimilar insulin use is not uncommon in Asia. Data exclusion due to incomplete capturing of brand names suggests possibly higher use. The multiple determinants of the quality of glycemic control call for establishment of prospective cohorts and diabetes registers to monitor the safety and efficacy of different brands of biosimilar insulin and their impacts on clinical outcomes.</P>
-
Full-space Cloud of Random Points with a Scrambling Metasurface
Li, Zile,Dai, Qi,Mehmood, Muhammad Q.,Hu, Guangwei,yanchuk, Boris Luk’,Tao, Jin,Hao, Chenglong,Kim, Inki,Jeong, Heonyeong,Zheng, Guoxing,Yu, Shaohua,Alù,, Andrea,Rho, Junsuk,Qiu, Cheng-Wei Nature Publishing Group UK 2018 Light, science & applications Vol.7 No.1
<▼1><P>With the rapid progress in computer science, including artificial intelligence, big data and cloud computing, full-space spot generation can be pivotal to many practical applications, such as facial recognition, motion detection, augmented reality, etc. These opportunities may be achieved by using diffractive optical elements (DOEs) or light detection and ranging (LIDAR). However, DOEs suffer from intrinsic limitations, such as demanding depth-controlled fabrication techniques, large thicknesses (more than the wavelength), Lambertian operation only in half space, etc. LIDAR nevertheless relies on complex and bulky scanning systems, which hinders the miniaturization of the spot generator. Here, inspired by a Lambertian scatterer, we report a Hermitian-conjugate metasurface scrambling the incident light to a cloud of random points in full space with compressed information density, functioning in both transmission and reflection spaces. Over 4044 random spots are experimentally observed in the entire space, covering angles at nearly 90°. Our scrambling metasurface is made of amorphous silicon with a uniform subwavelength height, a nearly continuous phase coverage, a lightweight, flexible design, and low-heat dissipation. Thus, it may be mass produced by and integrated into existing semiconductor foundry designs. Our work opens important directions for emerging 3D recognition sensors, such as motion sensing, facial recognition, and other applications.</P></▼1><▼2><P><B>Metasurfaces: scrambling light for 3D detection and recognition</B></P><P>Firing light at a manufactured 'metasurface'—one carrying patterns at a smaller scale than the wavelength of the light—fills large volumes of space with defined points of light, potentially improving 3-D recognition and sensor applications. Cheng-Wei Qui and colleagues at the National University of Singapore, with co-workers across Asia and in the USA, created their unique metasurface from amorphous silicon. Light is scattered from and transmitted through the material to generate a cloud of data points in the surrounding space in which the structure and motion of objects under study can be analyzed. The initial development work with this “scrambling metasurface” suggests it could improve pattern recognition, including face recognition, motion detection and augmented reality applications. The researchers describe how their innovation overcomes significant limitations of existing methods in these fields.</P></▼2>
-
Wayne Huey-Herng Sheu,Siew Pheng Chan,Bien J. Matawaran,Chaicharn Deerochanawong,Ambrish Mithal,Juliana Chan,Ketut Suastika,Chin Meng Khoo,Huu Man Nguyen,Ji Linong,Andrea Luk,윤건호 대한당뇨병학회 2020 Diabetes and Metabolism Journal Vol.44 No.1
The prevalence of obesity in Asia is of epidemic proportions, with an estimated 1 billion overweight/obese individuals in the region. The majority of patients with type 2 diabetes mellitus (T2DM) are overweight/obese, which increases the risk of cardiorenal outcomes in these patients; hence, sustained reductions in body weight and visceral adiposity are important management goals. However, most of the glucose-lowering therapies such as insulin, sulfonylureas, glinides, and thiazolidinediones induce weight gain, which makes the management of overweight/obese T2DM patients challenging. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are the only oral glucose-lowering agents that have been shown to reduce body weight and visceral adiposity. In addition, SGLT-2 inhibitors therapy reduces ectopic fat deposition and improves adipose tissue function and weight-related quality of life. In this article, we aim to consolidate the existing literature on the effects of SGLT-2 inhibitors in Asian patients with T2DM and to produce clinical recommendations on their use in overweight or obese patients with T2DM. Recommendations from international and regional guidelines, as well as published data from clinical trials in Asian populations and cardiovascular outcomes trials are reviewed. Based on the available data, SGLT-2 inhibitors represent an evidence-based therapeutic option for the management of overweight/obese patients with T2DM.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
